Mission Statement
To increase value through global activities ensuring the delivery of highly sensitive, novel and robust test(s) for early detection of cancer, assessment of cancer treatments and assistance in drug development.
-
Snapshot
Sienna is a small public unlisted company, based in Melbourne Australia. Sienna’s objective to identify, evaluate and commercialise cancer diagnostic tests is an exciting challenge which Sienna’s small, highly motivated and diverse team are equipped to tackle. After completing a large clinical study for its first test, Sienna seeks to partner out the sales and manufacturing of the test with a strong global organisation.
-
Bladder cancer
The gold standard in the monitoring and diagnosis of bladder cancer is cystoscopy, i.e. visual inspection and resection of cancerous lesions identified on the bladder wall using an endoscope. Several IVD tests (in-vitro diagnostic) for bladder cancer have attempted and failed to replace such invasive and subjective procedures. The Sienna test is expected to offer superior performance levels in the detection of bladder cancer, and thus ultimately serve as a valuable clinical tool.
-
Performance: the key to adoption
The development of a strategy driving rapid and sustained adoption of an IVD test in bladder cancer relies principally on clinical performance. Since 1997, six urine-based tests for markers have been approved for clinical use in the detection of bladder cancer with the expectation that fewer cystoscopies will be required. Yet universally, cystoscopy remains the gold standard.